¼¼°èÀÇ ±Ù½Ã ±³Á¤ ·»Áî ½ÃÀå
Myopia Control Lenses
»óǰÄÚµå : 1753016
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 467 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,039,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,117,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

±Ù½Ã ±³Á¤ ·»Áî ¼¼°è ½ÃÀåÀº 2030³â±îÁö 33¾ï ´Þ·¯¿¡ µµ´Þ

2024³â¿¡ 16¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ±Ù½Ã ±³Á¤ ·»Áî ¼¼°è ½ÃÀåÀº 2024-2030³â CAGR 12.3%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 33¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ÄÜÅÃÆ®·»Áî´Â CAGR 10.2%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 18¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµÇ°í ÀÖ½À´Ï´Ù. ¾È°æ ·»Áî ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£¿¡ CAGR 15.2%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 4¾ï 4,400¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR16.3%·Î ¼ºÀå ¿¹Ãø

¹Ì±¹ÀÇ ±Ù½Ã ±³Á¤ ·»Áî ½ÃÀåÀº 2024³â¿¡ 4¾ï 4,400¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGR 16.3%·Î ¼ºÀåÀ» Áö¼ÓÇÏ¿© 2030³â±îÁö 6¾ï 7,570¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 9.2%¿Í 10.8%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR ¾à 9.7%·Î ÃßÁ¤µË´Ï´Ù.

¼¼°èÀÇ ±Ù½Ã ±³Á¤ ·»Áî ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

±Ù½Ã°¡ Àü ¼¼°è °Ç°­ ¹®Á¦·Î ¶°¿À¸£´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

±Ù½Ã´Â ´Ü¼øÇÑ ±¼Àý À̻󿡼­ Àü ¼¼°è °øÁß º¸°Ç ¹®Á¦·Î º¯È­Çϰí ÀÖ½À´Ï´Ù. ƯÈ÷ µµ½Ã ȯ°æ¿¡ »ç´Â ¾î¸°ÀÌ¿Í Ã»¼Ò³âÀÇ ±Ù½Ã À¯º´·üÀÌ Áõ°¡Çϰí Àִµ¥, ÀÌ´Â Àå½Ã°£ ½ºÅ©¸° ³ëÃâ, ¾ß¿Ü Ȱµ¿ °¨¼Ò, Á¶±â ±³À°¿¡ ´ëÇÑ ¾Ð¹Ú µî »ýȰ½À°üÀÇ º¯È­·Î ÀÎÇÑ °ÍÀÔ´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)¿Í ÁÖ¿ä ¾È°ú ÇÐȸ´Â °í±Ù½Ã(-6.00D ÀÌ»ó)¸¦ ¸Á¸·¹Ú¸®, ³ì³»Àå, ±Ù½Ã¼º Ȳ¹Ýº¯¼º µî ÈÄõÀûÀ¸·Î ½É°¢ÇÑ ¾È°úÀû ÇÕº´ÁõÀ» À¯¹ßÇÏ´Â À§Çè¿äÀÎÀ¸·Î ÁöÀûÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È­´Â ´Ü¼øÇÑ ±³Á¤ÀÌ ¾Æ´Ñ Á¶±â °³ÀÔ°ú Àå±âÀûÀÎ ±Ù½Ã Á¶ÀýÀ» Àû±ØÀûÀ¸·Î ÃßÁøÇÏ´Â °è±â°¡ µÇ¾ú½À´Ï´Ù.

ÀÌ·¯ÇÑ ½Ã±Þ¼ºÀº ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ƯÈ÷ µÎµå·¯Áö¸ç, ÀϺΠÁö¿ª¿¡¼­´Â °íµîÇлýÀÇ 80% ÀÌ»óÀÌ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. À¯·´°ú ¹Ì±¹ ½ÃÀåµµ ²ÙÁØÈ÷ Áõ°¡Çϰí ÀÖÀ¸¸ç, °øÁß º¸°Ç ÇÁ·Î±×·¥¿¡ Á¶±â ½Ã·Â °Ë»ç ¹× ±Ù½Ã °ü¸® Àü·«À» µµÀÔÇϵµ·Ï Ã˱¸Çϰí ÀÖ½À´Ï´Ù. ¼Ò¾Æ ±Ù½ÃÀÇ ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ½Ã·Â ±³Á¤»Ó¸¸ ¾Æ´Ï¶ó ±Ù½Ã ÁøÇàÀÇ Áß¿äÇÑ ¿äÀÎÀÎ ¾ÈÃàÀå ¼ºÀåÀ» Àû±ØÀûÀ¸·Î Áö¿¬½ÃŰ´Â ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀνÄÀÌ ±âÁ¸ÀÇ ½Ã·Â±³Á¤ÀÌ ¾Æ´Ñ ±Ù½Ã Á¶ÀýÀ» ¸ñÀûÀ¸·Î Çϴ Ư¼ö ±¤ÇÐ Á¦Ç°ÀÇ ±â¼ú Çõ½Å¿¡ ¹ÚÂ÷¸¦ °¡Çϰí ÀÖ½À´Ï´Ù.

±Ù½Ã Á¶Àý ·»Áî´Â ½Ã·Â °ü¸®¸¦ ¾î¶»°Ô ÀçÁ¤ÀÇÇϰí ÀÖÀ»±î¿ä?

±Ù½Ã Á¶Àý ·»Áî´Â ¼±¸íÇÑ ½Ã¾ß¸¦ Á¦°øÇÒ »Ó¸¸ ¾Æ´Ï¶ó ¾î¸°ÀÌÀÇ ±Ù½Ã ÁøÇàÀ» ´ÊÃßµµ·Ï ¼³°èµÈ Ư¼ö ±¤ÇÐ Á¦Ç° Ä«Å×°í¸®ÀÔ´Ï´Ù. ÀÌÁß ÃÊÁ¡ ·»Áî, ´Ù ÃÊÁ¡ ·»Áî, µð Æ÷Ä¿½º ³»ÀåÇü ¸ÖƼ ºÎ¹®(DIMS) ·»Áî µîÀÌ ÀÖÀ¸¸ç, °¢°¢ ƯÁ¤ ±¤ÇÐ ¿ø¸®¸¦ ÀÌ¿ëÇÏ¿© ÁÖº¯ºÎ µð Æ÷Ä¿½º¸¦ Á¶ÀÛÇÏ¿© Ãà ¹æÇâÀÇ ´« ¼ºÀåÀ» ¾ïÁ¦ÇÕ´Ï´Ù. °¡Àå ÁÖ¸ñÇÒ ¸¸ÇÑ Çõ½ÅÀº DIMS ·»Áî·Î, Á߽ɺÎÀÇ ¼±¸íµµ¸¦ À¯ÁöÇϸ鼭 ±Ù½ÃÀÇ ÃÊÁ¡À» Á¶ÀýÇϱ⠶§¹®¿¡ »ýȰ½À°ü Àå¾Ö¸¦ ÃÖ¼ÒÈ­Çϸ鼭 Ä¡·á È¿°ú¸¦ ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

¿ø·¡ ³ë¾È¿ëÀ¸·Î ¼³°èµÈ ¼ÒÇÁÆ® ´ÙÃÊÁ¡ ÄÜÅÃÆ®·»Áî´Â ±Ù½Ã °ü¸®¿ëÀ¸·Î Àç»ç¿ëµÇ¾î ÀÓ»óÀûÀ¸·Î °ËÁõµÇ¾úÀ¸¸ç, Orthokeratology(Ortho-K)¿¡ ÇÊÀûÇÏ´Â È¿°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Ortho-K(Ortho-K) ·»Áî´Â °¢¸·ÀÇ ¸ð¾çÀ» ¹Ù²Ù°í ÃàÀÇ ¼ºÀåÀ» Áö¿¬½ÃŰ´Â ÇÏ·í¹ã Ä¡·á¹ýÀ¸·Î ÀαⰡ ³ôÀ¸¸ç, ¼Ò¾Æ ¹× û¼Ò³â¿¡°Ô ºñ¼ö¼úÀûÀÌ°í °¡¿ªÀûÀÎ ¼±ÅÃÁö¸¦ Á¦°øÇÕ´Ï´Ù. ±Ù½Ã ±³Á¤ ·»ÁîÀÇ °¡Àå Å« ÀåÁ¡Àº ¿¹¹æ °¡´É¼ºÀÔ´Ï´Ù. ´Ü¼øÈ÷ ½Ã·Â ÀúÇϸ¦ º¸¿ÏÇÏ´Â °ÍÀÌ ¾Æ´Ï¶ó ±Ù½Ã ÁøÇàÀ» À¯¹ßÇÏ´Â »ý¹°ÇÐÀû °úÁ¤¿¡ °³ÀÔÇÕ´Ï´Ù. ±× È¿´ÉÀ» µÞ¹ÞħÇÏ´Â ÀÓ»óÀû Áõ°Å°¡ Áõ°¡ÇÔ¿¡ µû¶ó Àü ¼¼°è °Ë¾È Ä¡·á ÇÁ·ÎÅäÄÝ¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù.

¾î¶² ±â¼úÀû, ÀÓ»óÀû Æ®·»µå°¡ äÅÃÀ» ÃËÁøÇϰí Àִ°¡?

±Ù½Ã Á¶Àý ·»Áî¿¡ ´ëÇÑ ÀÓ»óÀû ÁöÁö´Â Á¾´ÜÀû ¿¬±¸¿Í ±ÔÁ¦ ¸íȮȭ¸¦ ÅëÇØ Á¡Á¡ ´õ °­È­µÇ°í ÀÖ½À´Ï´Ù. ±¹Á¦ÀûÀÎ °¡À̵å¶óÀÎÀº ƯÈ÷ Ãʱ⠶Ǵ ÁøÇàÀÌ ºü¸¥ ±Ù½Ã ȯÀÚÀÇ 1Â÷ ¼±Åà ġ·á¹ýÀ¸·Î ±¤ÇÐ Á¦¾î ¹æ¹ýÀ» Æ÷ÇÔÇϵµ·Ï ÁøÈ­Çϰí ÀÖ½À´Ï´Ù. µ¿½Ã¿¡, ·»Áî ¼³°è ¹× Á¦Á¶ÀÇ ±â¼úÀû ¹ßÀüÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ ·»Áî´Â ´õ¿í Æí¸®Çϰí, Æí¾ÈÇϸç, È¿°úÀûÀÏ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÚÀ¯·Î¿î ÇüÅÂÀÇ µðÁöÅÐ ¼­ÆäÀ̰̽ú AI¸¦ Ȱ¿ëÇÑ ·»Áî Ä¿½ºÅ͸¶ÀÌ¡Àº Á¤È®ÇÑ ±¤ÇÐ ¿µ¿ªÀÇ ¹èÄ¡¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© °³º° »ç¿ëÀÚ¿¡°Ô ÃÖÀûÀÇ È¿°ú¸¦ º¸ÀåÇÕ´Ï´Ù.

½ÃÀå µµÀÔ Ãø¸é¿¡¼­ ¾È°æ ¼Ò¸ÅÁ¡, ¼Ò¾Æ ¾È°ú ÀÇ»ç, ºñÀüÄɾî üÀÎÀº Àü¿ë ¸ð´ÏÅÍ Ç÷£, ·»Áî Á¤¾×Á¦ µî ±Ù½Ã °ü¸®¿¡ ƯȭµÈ ¼­ºñ½º¸¦ ±¸ÃàÇϰí ÀÖ½À´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ Æ®·»µå´Â Ä¡·á °èȹÀÇ µðÁöÅÐ ÅëÇÕÀ¸·Î, ¼ÒÇÁÆ®¿þ¾î Ç÷§ÆûÀ» ÅëÇØ ÀÓ»óÀÇ¿Í º¸È£ÀÚ°¡ Ãà ±æÀÌÀÇ ÁøÇà°ú ¼øÀÀµµ¸¦ ½Ç½Ã°£À¸·Î ÃßÀûÇÒ ¼ö ÀÖ´Â ¼ÒÇÁÆ®¿þ¾î Ç÷§ÆûÀÌ µîÀåÇϰí ÀÖ½À´Ï´Ù. Çкθð¿Í Çб³ ½Ã½ºÅÛ¿¡¼­ ÀνÄÀÌ È®»êµÊ¿¡ µû¶ó ±Ù½Ã Á¶Àý ·»Áî¿Í °°Àº Áõ°Å¿¡ ±â¹ÝÇÑ ºñħ½ÀÀû °³ÀÔ¿¡ ´ëÇÑ ¼ö¿ä´Â ƯÈ÷ µµ½ÃÈ­µÇ°í ±â¼ú¿¡ Àͼ÷ÇÑ »ç¶÷µé »çÀÌ¿¡¼­ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù.

±Ù½Ã Á¶Àý ·»Áî ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ¿äÀÎÀº ¹«¾ùÀΰ¡?

±Ù½Ã Á¶Àý ·»Áî ½ÃÀåÀÇ ¼ºÀåÀº ·»Áî ¼³°èÀÇ Çõ½Å, ÃÖÁ¾ »ç¿ëÀÚ Ã¤Åà Áõ°¡, Áø´Ü »ýŰè È®Àå°ú °ü·ÃµÈ ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ¼ºÀå ¿äÀÎ Áß Çϳª´Â ·»Áî Á¦Á¶ ¹æ¹ýÀÇ ±Þ¼ÓÇÑ ±â¼ú ¹ßÀüÀ¸·Î Æí¾ÈÇÔ°ú ¹ÌÀû °¨°¢À» ÇØÄ¡Áö ¾ÊÀ¸¸é¼­µµ Á¤È®ÇÑ ±Ù½Ã µðÆ÷Ä¿½º Á¦¾î°¡ °¡´ÉÇØÁ³À¸¸ç, DIMS ¹× ÀÌÁß ÃÊÁ¡ ¼³°è¿Í °°Àº ·»ÁîÀÇ »ó¿ëÈ­´Â ÀÓ»ó½ÃÇè µ¥ÀÌÅÍ¿¡ ÀÇÇØ °­·ÂÇÏ°Ô µÞ¹ÞħµÇ¾î ¾È°ú Àü¹®°¡¿Í º¸È£ÀÚÀÇ ½Å·Ú¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. °­È­Çϰí ÀÖ½À´Ï´Ù.

¼Ò¾Æ ¾È°ú Ŭ¸®´Ð, °Ë¾È üÀÎ, ±³À° ¹× º¸°Ç ÇÁ·Î±×·¥¿¡ ´ëÇÑ ÃÖÁ¾ ¿ëµµÀÇ È®´ëµµ ½ÃÀå ÁøÀÔÀ» °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÀÌÇØ°ü°èÀÚµéÀº Á¤±âÀûÀÎ ¾È°ú °ËÁø ¹× Ãà ±æÀÌ ¸ð´ÏÅ͸¦ ÅëÇØ Áö¿øµÇ´Â Á¾ÇÕÀûÀÎ ½Ã·Â °ü¸® ÆÐŰÁöÀÇ ÀϺηΠ±Ù½Ã Á¶Àý ·»Á ÅëÇÕÇϰí ÀÖ½À´Ï´Ù. µðÁöÅÐ °Ç°­ Ç÷§Æû°ú Ä¿³ØÆ¼µå µð¹ÙÀ̽º´Â ·»Áî »ç¿ë ¹× Ä¡·á ¼øÀÀµµ¿¡ ´ëÇÑ ½Ç½Ã°£ Çǵå¹éÀ» Á¦°øÇÏ¿© »ç¿ëÀÚÀÇ Àå±âÀûÀÎ Âü¿©¸¦ À¯µµÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ƯÁ¤ ·»Áî À¯Çü¿¡ ´ëÇÑ CE ¸¶Å· ¹× FDA ½ÂÀΰú °°Àº ÁÖ¿ä ½ÃÀå¿¡¼­ÀÇ ±ÔÁ¦ ½ÂÀÎÀº ½Å·Ú¼ºÀ» ³ôÀÌ°í ±¹°æÀ» ÃÊ¿ùÇÑ È®ÀåÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î ±Ù½Ã ±³Á¤ ·»Áî´Â ÁøÇ༺ ±Ù½Ã ÅðÄ¡¸¦ À§ÇÑ Àü ¼¼°è ÅõÀïÀÇ Áß½ÉÃàÀ¸·Î ÀÚ¸®¸Å±èÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

Á¦Ç° À¯Çü(ÄÜÅÃÆ®·»Áî, ¾È°æ ·»Áî);·»Áî À¯Çü(´ÙÃÊÁ¡ ·»Áî, °¢¸·±¼Àý ±³Á¤ ·»Áî, ÀÌÁß ÃÊÁ¡ ·»Áî, ÁÖº¯ºÎ ÃÊÁ¡ ·»Áî);¿¬·ÉÃþ(¾ÆÀÌ, ¼ºÀÎ);ÆÇ¸Åä³Î(°Ë¾È Ŭ¸®´Ð, ¾È°æ ¼Ò¸ÅÁ¡, ¿Â¶óÀÎ ¼Ò¸Å)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 41°³»ç)

AI ÅëÇÕ

¿ì¸®´Â À¯È¿ÇÑ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AIÅø¿¡ ÀÇÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ º¯ÇõÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM³ª ¾÷°è °íÀ¯ SLM¸¦ Á¶È¸ÇÏ´Â ÀϹÝÀûÀÎ ±Ô¹ü¿¡ µû¸£´Â ´ë½Å¿¡, ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾ç ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî, Àü ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¼öÀÍ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Myopia Control Lenses Market to Reach US$3.3 Billion by 2030

The global market for Myopia Control Lenses estimated at US$1.6 Billion in the year 2024, is expected to reach US$3.3 Billion by 2030, growing at a CAGR of 12.3% over the analysis period 2024-2030. Contact Lens, one of the segments analyzed in the report, is expected to record a 10.2% CAGR and reach US$1.8 Billion by the end of the analysis period. Growth in the Spectacle Lens segment is estimated at 15.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$444.0 Million While China is Forecast to Grow at 16.3% CAGR

The Myopia Control Lenses market in the U.S. is estimated at US$444.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$675.7 Million by the year 2030 trailing a CAGR of 16.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 10.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.7% CAGR.

Global Myopia Control Lenses Market - Key Trends & Drivers Summarized

Why Is Myopia Emerging as a Critical Global Health Challenge?

Myopia, or nearsightedness, has transitioned from a simple refractive error to a public health concern of global proportions. Its increasing prevalence, especially among children and adolescents in urban environments, is being driven by lifestyle changes such as prolonged screen exposure, reduced outdoor activity, and early educational pressure. The World Health Organization and major ophthalmology associations have flagged high myopia (−6.00D or greater) as a risk factor for severe ocular complications later in life, including retinal detachment, glaucoma, and myopic maculopathy. This shift has sparked a proactive push toward early intervention and long-term myopia control rather than mere correction.

The urgency is especially pronounced in Asia-Pacific, where over 80% of high school students in some regions are affected. Western markets, too, are witnessing a steady rise, prompting public health programs to incorporate early vision screening and myopia management strategies. The rising burden of pediatric myopia is intensifying demand for solutions that not only correct vision but also actively slow axial elongation of the eyeball-a key factor in myopia progression. This awareness is fueling innovation in specialized optical products aimed at myopia control rather than traditional vision correction.

How Are Myopia Control Lenses Redefining Vision Management?

Myopia control lenses are a category of specialized optical products designed to not only provide clear vision but also to slow down the progression of myopia in children. These include dual-focus, multifocal, and defocus-incorporated multiple-segment (DIMS) lenses, each leveraging specific optical principles to manipulate peripheral defocus and reduce axial eye growth. Among the most notable breakthroughs are DIMS lenses, which create a myopic defocus while maintaining central clarity, thus delivering therapeutic benefit with minimal lifestyle disruption.

Soft multifocal contact lenses, originally designed for presbyopia, have been repurposed and clinically validated for myopia management, showing efficacy comparable to orthokeratology (Ortho-K). Ortho-K lenses themselves remain a popular overnight treatment that reshapes the cornea to slow axial elongation, offering a non-surgical, reversible option for children and adolescents. What sets myopia control lenses apart is their preventive potential: rather than merely compensating for poor vision, they intervene in the biological processes that drive progressive myopia. Increasing clinical evidence supporting their effectiveness is propelling their inclusion in optometric care protocols worldwide.

Which Technological and Clinical Trends Are Driving Adoption?

The clinical endorsement of myopia control lenses is increasingly supported by longitudinal studies and growing regulatory clarity. International guidelines are evolving to include optical control methods as first-line therapies, particularly for early-onset and fast-progressing cases. At the same time, technological advancements in lens design and manufacturing are making these lenses more accessible, comfortable, and effective. Free-form digital surfacing and AI-powered lens customization are enabling precise optical zone placement, ensuring optimal efficacy for individual users.

From a market adoption perspective, optical retailers, pediatric ophthalmologists, and vision care chains are building specialized services around myopia management, including dedicated monitoring plans and subscription-based access to lenses. Another critical trend is the digital integration of treatment plans, where software platforms now allow clinicians and parents to track axial length progression and compliance in real time. As awareness spreads among parents and school systems, the demand for evidence-based, non-invasive interventions like myopia control lenses continues to surge, particularly in urbanized and tech-savvy populations.

What Factors Are Fueling Growth in the Myopia Control Lenses Market?

The growth in the myopia control lenses market is driven by several factors related to innovation in lens design, rising end-use adoption, and an expanding diagnostic ecosystem. One of the primary growth catalysts is the rapid technological advancement in lens fabrication methods, enabling precise myopic defocus control without compromising comfort or aesthetics. The commercialization of lenses like DIMS and dual-focus designs, with strong backing from clinical trial data, is reinforcing trust among eye care professionals and parents alike.

End-use expansion into pediatric vision clinics, optometry chains, and educational health programs is also accelerating market uptake. These stakeholders are increasingly integrating myopia control lenses as part of holistic vision care packages, supported by recurring eye exams and axial length monitoring. Digital health platforms and connected devices now offer real-time feedback on lens usage and treatment adherence, encouraging long-term user engagement. Furthermore, regulatory greenlights in key markets, including CE marking and FDA approvals for specific lens types, are bolstering confidence and enabling cross-border expansion. Together, these developments are cementing the role of myopia control lenses as a central pillar in the global fight against progressive myopia.

SCOPE OF STUDY:

The report analyzes the Myopia Control Lenses market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Contact Lens, Spectacle Lens); Lens Type (Multifocal Lenses, Orthokeratology Lenses, Dual-focus Lenses, Peripheral Defocus Lenses); Age Group (Children, Adults); Distribution Channel (Optometry Clinics, Optical Retail Stores, Online Retail)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â